Sage announces appointments

Sage Therapeutics, a clinical-stage biopharmaceutical company developing medicines for central nervous system disorders, has announced the appointment of Michael Cloonan as chief business officer; Dr. Christopher Silber as senior vice president for clinical development; Amy Schacterle as senior vice president for regulatory affairs and quality assurance; Paul Hodgkins as vice president for health economics and outcomes research and value demonstration; and Frank Sanders as vice president for sales and marketing.